MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Net Income
-$107,322,000K
Unit: Thousand (K) dollars
Income Statement
2025-12-31
2024-12-31
Revenues
0
131,161
Research and development expense
0
227,702
Selling, general and administrative
0
115,450
Cost of product revenue
0
5,279
Total cost and operating expenses
0
348,431
Loss from operations
0
-217,270
Other income (expense), net
0
1,217
Investment income, net
0
19,701
Gain from sale of priority review voucher
0
108,000
Total non-operating income, net
0
128,918
Loss before income taxes
0
88,352
Income tax expense
0
7,144
Net loss
-107,322,000
-95,496
Basic EPS
-
-1.02
Diluted EPS
-
-1.02
Basic Average Shares
-
93,234,195
Diluted Average Shares
-
93,234,195
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Net loss-$107,322,000K (-112283.76%↓ Y/Y)something is missing-$107,322,000K

Day One Biopharmaceuticals, Inc. (DAWN)

Day One Biopharmaceuticals, Inc. (DAWN)